Ribociclib

In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.

SAN DIEGO — The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than reported in prior clinical trials, according to study results.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, discussed “interesting updates” from the NATALEE trial presented at ESMO Congress.

This year’s San Antonio Breast Cancer Symposium featured several high-impact abstracts.

SAN ANTONIO — The addition of ribociclib to endocrine therapy conferred durable benefit to patients with hormone receptor-positive, HER2-negative early breast cancer, according to findings presented at San Antonio Breast Cancer Symposium.

Nearly 7,000 abstracts had been submitted for presentation at this year’s ASCO Annual Meeting.

CHICAGO — First-line use of cyclin-dependent kinase 4/6 inhibitors did not confer significant benefit vs. second-line use when added to endocrine therapy for women with hormone receptor-positive, HER2-negative, advanced breast cancer.

CHICAGO — The addition of ribociclib to endocrine therapy improved invasive DFS vs. endocrine therapy alone in patients with hormone receptor-positive, HER2-negative early-stage breast cancer.

The addition of ribociclib to adjuvant endocrine therapy significantly reduced the risk for disease recurrence among patients with hormone receptor-positive, HER2-negative early breast cancer, according to the agent’s manufacturer.